Neurizon Secures AU$1.5 million Non-Dilutive Loan Against 2025 R&D Tax Rebate

Neurizon Therapeutics Limited (ASX: NUZ), has executed an AU$1.5 million loan agreement with specialist R&D financier Radium Capital. The facility is secured against the Company’s expected 2025 Australian Federal Government R&D Tax Incentive rebate and represents less than 30% of the anticipated refund. The loan, carrying an interest rate of 17% per annum, will be repaid from the proceeds of the 2025 R&D Tax Rebate and provides non-dilutive funding to support Neurizon’s ongoing clinical and research programs.

Managing Director and CEO Dr. Michael Thurn said the arrangement strengthens the Company’s short-term liquidity while maintaining capital efficiency and minimising shareholder dilution. He added that the financing will enable Neurizon to progress its pipeline of neurodegenerative disease therapies ahead of the receipt of the R&D rebate.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com